Marshall Wace
OKUR

Marshall Wace’s OnKure Therapeutics OKUR Stock Holding History

Marshall Wace’s Portfolio OKUR Stock Details OKUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$729K Buy
159,881
+123,437
+339% +$530K ﹤0.01% 2346
2026
Q1 		$151K Buy
+36,444
New +$113K ﹤0.01% 2835

Other funds holding OKUR

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Marshall Wace's OKUR Position: Q2 2026 in Review

Marshall Wace increased its OnKure Therapeutics (OKUR) stake by 339% in Q2 2026, buying an estimated $530K and bringing the position to 159,881 shares worth $729K. The position accounts for ﹤0.01% of the portfolio, ranked #2346.

Marshall Wace first reported a position in OKUR in Q1 2026 and has held it in 2 quarters since. 75 funds tracked by Wall St. Rank hold OKUR as of Q2 2026.

  • Marshall Wace held 159,881 shares of OnKure Therapeutics worth $729K as of Q2 2026.
  • Marshall Wace bought 123,437 OnKure Therapeutics shares in Q2 2026, an estimated $530K.
  • OnKure Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #2346 holding.
  • Marshall Wace first reported a position in OnKure Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 75 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.